glutathione s transferase uniprot Overexpression of S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications Characterizing and Tailoring the Substrate

Radiocontrast nephropathy prevention (off-label)

The best-documented axis of BPC-157

Only testing systems that are glucose-specific should be used in patients receiving HepaGam B

User experimentation suggests that longer initial treatment periods (6+ months continuous) support better benefit retention during subsequent breaks, complete discontinuation breaks of 1-2 months show acceptable benefit maintenance for most users, and very extended breaks (3-6+ months) increase risk of regression toward pre-treatment baseline particularly for short initial treatment courses

Oral BPC-157 capsule products face an additional challenge: excipient interactions and moisture ingress through capsule walls during storage